iScience (Sep 2024)

Feasibility and barriers to rapid establishment of patient-derived primary osteosarcoma cell lines in clinical management

  • Thomas Chow,
  • William Humble,
  • Enrico Lucarelli,
  • Carmine Onofrillo,
  • Peter F. Choong,
  • Claudia Di Bella,
  • Serena Duchi

Journal volume & issue
Vol. 27, no. 9
p. 110251

Abstract

Read online

Summary: Osteosarcoma is a highly aggressive primary bone tumor that has seen little improvement in survival rates in the past three decades. Preclinical studies are conducted on a small pool of commercial cell lines which may not fully reflect the genetic heterogeneity of this complex cancer, potentially hindering translatability of in vitro results. Developing a single-site laboratory protocol to rapidly establish patient-derived primary cancer cell lines (PCCL) within a clinically actionable time frame of a few weeks will have significant scientific and clinical ramifications. These PCCL can widen the pool of available cell lines for study while patient-specific data could derive therapeutic correlation. This endeavor is exceedingly challenging considering the proposed time constraints. By proposing key definitions and a clear theoretical framework, this evaluation of osteosarcoma cell line establishment methodology over the past three decades assesses feasibility by identifying barriers and suggesting solutions, thereby facilitating systematic experimentation and optimization.

Keywords